Hyperthermic intraperitoneal chemotherapy is an independent risk factor for development of acute kidney injury

Dagel, Tuncay; Misirlioglu, Selim; Tanju, Serhan; AFŞAR, Barış; Selcukbiriciks, Fatih; Erus, Suat; Vatansever, Dogan; Bank, Emre; Taskiran, Cagatay; Dilege, Sukru; Mandel, Nil; Bugra, Dursun; Yalti, Tunc; Kanbay, Mehmet

Hyperthermic intraperitoneal chemotherapy is an independent risk factor for development of acute kidney injury

Dagel T., Misirlioglu S., Tanju S., AFŞAR B., Selcukbiriciks F., Erus S., ...Daha Fazla

JOURNAL OF BUON, cilt.23, sa.5, ss.1528-1533, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 23 Sayı: 5
Basım Tarihi: 2018
Dergi Adı: JOURNAL OF BUON
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1528-1533
Süleyman Demirel Üniversitesi Adresli: Evet

Özet

Purpose: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) or hyperthermic intrapleural chemotherapy (HIC) has been established as the new treatment modality for selected patients with peritoneal and pleural malignancies. The purpose of the study was to compare the development of acute kidney injury (AKI) in patients who received intravenous cisplatin alone, HIPEC and underwent surgery.